TA
| Investor | Type | Est. change | Change | Δ Own | Date | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Millennium Management LLC
· Added
+$12M
Change
+2.1M
Date
Q1 2026
|
Millennium Management LLC | Added· Q1 2026 | +$12M | +2.1M | – | Q1 2026 | |||||
|
Aigh Capital Management LLC
· New
+$9.6M
Change
+1.6M
Date
Q1 2026
|
Aigh Capital Management LLC | New· Q1 2026 | +$9.6M | +1.6M | – | Q1 2026 | |||||
|
Driehaus Capital Management LLC
· Exited
−$7.5M
Change
−1.3M
Δ Own
−100.0%
Date
Q1 2026
|
Driehaus Capital Management LLC | Exited· Q1 2026 | −$7.5M | −1.3M | −100.0% | Q1 2026 | |||||
|
Point72 Asset Management, L.P.
· Added
+$6.7M
Change
+1.1M
Δ Own
+4001.2%
Date
Q1 2026
|
Point72 Asset Management, L.P. | Added· Q1 2026 | +$6.7M | +1.1M | +4001.2% | Q1 2026 | |||||
|
Adage Capital Partners Gp, L.L.C.
· Exited
−$6.2M
Change
−1.0M
Δ Own
−100.0%
Date
Q1 2026
|
Adage Capital Partners Gp, L.L.C. | Exited· Q1 2026 | −$6.2M | −1.0M | −100.0% | Q1 2026 | |||||
|
Patient Square Capital LP
· New
+$6.1M
Change
+1.0M
Date
Q1 2026
|
Patient Square Capital LP | New· Q1 2026 | +$6.1M | +1.0M | – | Q1 2026 | |||||
|
BlackRock
· Added
+$5.8M
Change
+986K
Date
Q1 2026
|
BlackRock | Added· Q1 2026 | +$5.8M | +986K | – | Q1 2026 | |||||
|
Catalio Capital Management, LP
· Reduced
−$5.1M
Change
−866K
Date
Q1 2026
|
Catalio Capital Management, LP | Reduced· Q1 2026 | −$5.1M | −866K | – | Q1 2026 | |||||
|
J. Goldman & Co LP
· New
+$5.1M
Change
+856K
Date
Q1 2026
|
J. Goldman & Co LP | New· Q1 2026 | +$5.1M | +856K | – | Q1 2026 | |||||
|
Maven Securities Ltd
· Exited
−$4.5M
Change
−755K
Δ Own
−100.0%
Date
Q1 2026
|
Maven Securities Ltd | Exited· Q1 2026 | −$4.5M | −755K | −100.0% | Q1 2026 | |||||
|
Sphera Funds Management Ltd.
· Exited
−$3.8M
Change
−650K
Δ Own
−100.0%
Date
Q1 2026
|
Sphera Funds Management Ltd. | Exited· Q1 2026 | −$3.8M | −650K | −100.0% | Q1 2026 | |||||
|
Marshall Wace, LLP
· Reduced
−$3.2M
Change
−534K
Date
Q1 2026
|
Marshall Wace, LLP | Reduced· Q1 2026 | −$3.2M | −534K | – | Q1 2026 | |||||
|
Vanguard
· Added
+$3.0M
Change
+501K
Date
Q1 2026
|
Vanguard | Added· Q1 2026 | +$3.0M | +501K | – | Q1 2026 | |||||
|
Integral Health Asset Management, LLC
· Reduced
−$3.0M
Change
−500K
Date
Q1 2026
|
Integral Health Asset Management, LLC | Reduced· Q1 2026 | −$3.0M | −500K | – | Q1 2026 | |||||
|
State Street
· Added
+$2.6M
Change
+434K
Date
Q1 2026
|
State Street | Added· Q1 2026 | +$2.6M | +434K | – | Q1 2026 | |||||
| Insider | Title | Type | Price | Qty | Value | Owned | ΔOwn | Trade date | Filed date | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shefferman Jesse
· Director
4 operations
-30K
|
Shefferman Jesse | Director | 4 operations | – | -30K | – | 692K | −4.2% | Jun 30, 2026 | Jul 1, 2026 | |||||||||
|
Shefferman Jesse
· Director
Sell
−$882K
|
Shefferman Jesse | Director | Sell | $4.09 | −216K | −$882K | 722K | −23.0% | Jun 29, 2026 | Jul 1, 2026 | |||||||||
|
Shefferman Jesse
· Director
2 operations
0
|
Shefferman Jesse | Director | 2 operations | $1.91 | 0 | – | 141K | – | Jun 29, 2026 | Jul 1, 2026 | |||||||||
|
Levy Richard S.
· Director
Grant (A)
31K
|
Levy Richard S. | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Solomon Michael Edward
· Director
Grant (A)
31K
|
Solomon Michael Edward | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Smith Cynthia
· Director
Grant (A)
31K
|
Smith Cynthia | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Sargen Gregory
· Director
Grant (A)
31K
|
Sargen Gregory | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Huang Jane
· Director
Grant (A)
31K
|
Huang Jane | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Garceau Roger
· Director
Grant (A)
31K
|
Garceau Roger | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Flannelly Barry P.
· Director
Grant (A)
31K
|
Flannelly Barry P. | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Beshar Luke M.
· Director
Grant (A)
31K
|
Beshar Luke M. | Director | Grant (A) | – | 31K | – | 31K | – | Jun 15, 2026 | Jun 16, 2026 | |||||||||
|
Conkling William
· Officer
Tax withholding or exercise payment (F)
-$26K
|
Conkling William | Officer | Tax withholding or exercise payment (F) | $4.34 | -6K | -$26K | 70K | – | Jun 2, 2026 | Jun 3, 2026 | |||||||||
|
Zummo Jacqueline
· Officer
Sell
−$6K
|
Zummo Jacqueline | Officer | Sell | $5.40 | −1K | −$6K | 95K | – | Apr 8, 2026 | Apr 9, 2026 | |||||||||
|
Zummo Jacqueline
· Officer
Sell
−$119K
|
Zummo Jacqueline | Officer | Sell | $5.26 | −23K | −$119K | 96K | – | Apr 1, 2026 | Apr 2, 2026 | |||||||||
|
Fry Hannah
· Officer
Tax withholding or exercise payment (F)
-$10K
|
Fry Hannah | Officer | Tax withholding or exercise payment (F) | $6.67 | -1K | -$10K | 43K | – | Jan 26, 2026 | Jan 27, 2026 | |||||||||
118 reporting institutions disclosed TARA position changes in the Q1 2026 snapshot.
For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.
An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.
Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.
Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.
A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.